All In Biotech

Drug Trial Radar · NCT07680790

Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

A Phase III, Randomized, Open-label Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy as First-Line Therapy in Patients With EGFR-Mutant Locally Advanced or Metastatic Non-small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 850 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

850

Planned (sponsor's estimate)

Start

Sep 8, 2026

Primary completion

Dec 30, 2031

Study completion Dec 30, 2031

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jul 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, locally advanced or metastatic EGFR-mutant NSCLC, compared to osimertinib alone or osimertinib combined with platinum-based chemotherapy

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • Iza-brenDrug

    Specified dose on specified days

  • OsimertinibDrug

    Specified dose on days

  • PemetrexedDrug

    Specified dose on specified days

  • CarboplatinDrug

    Specified dose on specified days

  • CisplatinDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) using blinded independent central review (BICR) assessment as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)Time frame: Up to approximately 3 years

Locations

205 sites in 16 countries. Site status is shown where the registry gives one.

  • Local Institution - 0212

    Beverly Hills, California · Not yet recruiting

  • Local Institution - 0504

    Fullerton, California · Not yet recruiting

  • Local Institution - 0357

    La Jolla, California · Not yet recruiting

  • Rocky Mountain Cancer Centers

    Boulder, Colorado · Recruiting

  • Local Institution - 0161

    Washington D.C., District of Columbia · Not yet recruiting

  • Local Institution - 0527

    Fort Myers, Florida · Not yet recruiting

  • Local Institution - 0366

    Orlando, Florida · Not yet recruiting

  • Cancer Care Centers of Brevard - Rockledge

    Palm Bay, Florida · Recruiting

  • Local Institution - 0526

    St. Petersburg, Florida · Not yet recruiting

  • Local Institution - 0524

    West Palm Beach, Florida · Not yet recruiting

  • Local Institution - 0185

    Chicago, Illinois · Not yet recruiting

  • Local Institution - 0207

    Ottawa, Illinois · Not yet recruiting

  • Local Institution - 0503

    Baltimore, Maryland · Not yet recruiting

  • Local Institution - 0537

    Baltimore, Maryland · Not yet recruiting

  • Local Institution - 0523

    Silver Spring, Maryland · Not yet recruiting

  • Local Institution - 0521

    Edina, Minnesota · Not yet recruiting

  • Local Institution - 0364

    Saint Paul, Minnesota · Not yet recruiting

  • Washington University School Of Medicine

    St Louis, Missouri · Recruiting

  • Local Institution - 0402

    Omaha, Nebraska · Not yet recruiting

  • Local Institution - 0290

    Lebanon, New Hampshire · Not yet recruiting

  • Local Institution - 0183

    New Brunswick, New Jersey · Not yet recruiting

  • Local Institution - 0153

    New York, New York · Not yet recruiting

  • Local Institution - 0157

    The Bronx, New York · Not yet recruiting

  • Local Institution - 0385

    Charlotte, North Carolina · Not yet recruiting

  • Local Institution - 0438

    Sandusky, Ohio · Not yet recruiting

  • Local Institution - 0404

    Portland, Oregon · Not yet recruiting

  • Local Institution - 0487

    Easton, Pennsylvania · Not yet recruiting

  • Local Institution - 0200

    Sioux Falls, South Dakota · Not yet recruiting

  • Local Institution - 0199

    Memphis, Tennessee · Not yet recruiting

  • Texas Oncology

    Beaumont, Texas · Recruiting

  • Texas Oncology - DFW

    Dallas, Texas · Recruiting

  • Texas Oncology - San Antonio

    San Antonio, Texas · Recruiting

  • Local Institution - 0411

    Salt Lake City, Utah · Not yet recruiting

  • Local Institution - 0165

    Fairfax, Virginia · Not yet recruiting

  • Local Institution - 0530

    Fairfax, Virginia · Not yet recruiting

  • Shenandoah Oncology, P.C. (Shenandoah Oncology Associates, P.C.)

    Winchester, Virginia · Recruiting

  • Local Institution - 0283

    Seattle, Washington · Not yet recruiting

  • Local Institution - 0502

    Morgantown, West Virginia · Not yet recruiting

  • Local Institution - 0086

    Buenos Aires, Argentina · Not yet recruiting

  • Local Institution - 0432

    Buenos Aires, Argentina · Not yet recruiting

Showing 40 of 205 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.